Taiwan medical-device developer building accelerator-based Boron Neutron Capture Therapy (BNCT) systems for cancer treatment.
Taiwan medical-device developer building accelerator-based Boron Neutron Capture Therapy (BNCT) systems for cancer treatment.
Sells treatment systems built around a particle accelerator, so each sale is a single large project that can take years from order to hospital installation, with ongoing service after that. Its income waits on regulatory approvals and installations.
Moat: narrow (IP / patents, regulatory licence). BNCT requires specialized accelerator technology and regulatory clearance, limiting competitors.
Headquarters: Hsinchu, Taiwan · Employees: 111
Size Heron Neutron Medical (7799.TW) is a Taiwan Industrials company (Miscellaneous Commercial Services) with a market value of $2.15B, the 153rd largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$476.00 on 18 Nov 2026.
Performance Over six months the shares gained 56.1%, against -4.4% for the median peer and -3.4% for the Taiwan market (cap-weighted) — highest of 21 in its peer set.
Growth The operating margin is -5,318.9% (peer median 15.5%).
Valuation It trades at 6.38× book value against a peer median of 3.17× (6th most expensive of 21).
Price implies The share price implies a return on equity of about 23.6%; Heron Neutron Medical delivers -3.1%, so the price asks more than the business earns today.
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NT$9.61M | NT$10.3M | NT$0 | NT$238,000 | NT$0 |
| Revenue growth | — | — | -100% | — | — |
| Gross profit | -NT$60.0M | -NT$63.1M | -NT$24.2M | -NT$15.3M | -NT$14.0M |
| EBITDA | -NT$463M | -NT$495M | -NT$238M | -NT$114M | -NT$73.8M |
| Net income | -NT$365M | -NT$482M | -NT$260M | -NT$126M | -NT$86.2M |
| Free cash flow | -NT$92.9M | -NT$512M | -NT$309M | -NT$260M | -NT$355M |
| Capital expenditure | NT$652M | NT$30.1M | NT$49.0M | NT$56.2M | NT$114M |
| Total debt | NT$240M | NT$7.23M | NT$9.51M | NT$13.4M | NT$17.3M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | ROE | Price / book | Implied ROE |
|---|---|---|---|---|---|---|
| Heron Neutron Medical 7799.TW | $2.15B | +56% | n/a | -3% | 6.38× | 23.6% |
| Sumitomo Heavy Industries 6302.T | $3.62B | -9% | +9% | 6% | 0.81× | 10.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 7799.TW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +5.1% | -1.1% | 6th highest of 21 |
| 6-month return | +56.1% | -4.4% | highest of 21 |
| Return on equity | -3.1% | 11.5% | 2nd lowest of 21 |
| Price / book | 6.38× | 3.17× | 6th most expensive of 21 |
| ROE the price implies | 23.6% | 21.6% | 11th least demanding of 21 |
| ROE delivered | -3.1% | 10.7% | 2nd lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | ROE | Price / book | Implied ROE | Delivered ROE |
|---|---|---|---|---|---|---|---|---|
| Heron Neutron Medical 7799.TW | Taiwan | $2.15B | +56% | n/a | -3% | 6.38× | 23.6% | -3.1% |
| TIC Solutions TIC | United States | $2.15B | +14% | +39% | -6% | 1.02× | 13.9% | -5.5% |
| Ardentec 3264.TWO | Taiwan | $2.17B | -26% | +32% | 21% | 3.04× | 24.6% | 20.7% |
| Sigurd Microelectronics 6257.TW | Taiwan | $2.10B | -28% | +18% | 20% | 2.59× | 18.0% | 20.0% |
| Biocytogen Pharmaceuticals (Beijing) 688796.SS | China | $2.09B | -33% | +40% | 22% | 11.62× | 126.9% | 21.8% |
| Suzhou Nanomicro Technology 688690.SS | China | $2.08B | -1% | +26% | 12% | 6.37× | 70.8% | 12.3% |
| International Gemological Institute IGIL.NS | India | $2.05B | +33% | +21% | 45% | 10.96× | 103.5% | n/a |
| Sagility SAGILITY.NS | India | $2.26B | +7% | +28% | 11% | 2.07× | 18.5% | 10.7% |
| Firstsource Solutions FSL.NS | India | $2.04B | +13% | +20% | 16% | 3.86× | 46.7% | 15.7% |
| Hui Lyu Ecological Technology Groups 001267.SZ | China | $2.28B | -68% | +90% | 6% | 9.25× | 72.1% | 6.0% |
| KWS SAAT SE & Co KGaA KWS.DE | Germany | $2.30B | -11% | -1% | 8% | 1.24× | 5.4% | 8.0% |
| China Automotive Engineering Research Institute 601965.SS | China | $2.31B | -11% | +12% | 14% | 1.84× | 9.6% | 13.7% |
| CECEP Environmental Protection 300140.SZ | China | $2.37B | -23% | -2% | 6% | 1.08× | 9.3% | 6.3% |
| Shanghai GenTech 688596.SS | China | $2.37B | +4% | +4% | 8% | 3.31× | 32.4% | 8.1% |
| V2X VVX | United States | $2.45B | +9% | +13% | 9% | 2.10× | 10.5% | 8.8% |
| Syngene International SYNGENE.NS | India | $1.88B | -8% | -6% | 4% | 3.60× | 48.0% | 3.9% |
| Jiangsu Guotai International 002091.SZ | China | $1.87B | -15% | +7% | 7% | 0.76× | 6.0% | 6.9% |
| Insperity NSP | United States | $1.86B | +55% | +2% | 5% | 41.04× | 190.7% | 4.6% |
| Visional 4194.T | Japan | $2.50B | +33% | +24% | 24% | 4.61× | 15.6% | 24.1% |
| Jiangsu Boqian New Materials Stock 605376.SS | China | $2.52B | -46% | +76% | 17% | 8.77× | 139.5% | 16.5% |
| Prosegur Compania de Seguridad PSG.MC | Spain | $1.82B | +10% | +4% | 16% | 2.03× | 16.4% | 16.1% |